Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis  Robert Wolk, MD, PhD, DSc, Ehrin J.

Published byMichelle Sauvé Modified over 6 years ago

Similar presentations

Presentation on theme: "Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis  Robert Wolk, MD, PhD, DSc, Ehrin J."— Presentation transcript:

1 Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis  Robert Wolk, MD, PhD, DSc, Ehrin J. Armstrong, MD, MSc, Peter R. Hansen, MD, PhD, DMSci, Bruce Thiers, MD, Shuping Lan, MA, MPH, Anna M. Tallman, PharmD, Mandeep Kaur, MD, MS, Svitlana Tatulych, MD  Journal of Clinical Lipidology  Volume 11, Issue 5, Pages (September 2017) DOI: /j.jacl Copyright © 2017 National Lipid Association Terms and Conditions

2 Figure 1 Baseline values and percent change from baseline in traditionally measured lipid parameters and lipoproteins at weeks 4 and 16 for all patients in the OPT Pivotal 1 study. †Apo CIII data are reported from patients included in the lipid-related parameter analysis group; all other parameters are reported for the total OPT Pivotal 1 study population. *P < .05; **P < .001; ***P < .0001 vs placebo. Least squares means and corresponding SE and P values are derived from a mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value, repeated measures for visit (nested within subject), and an unstructured covariance matrix Error bars represent ± SE. Apo, apolipoprotein; BID, twice daily; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SE, standard error; TC, total cholesterol; TG, triglycerides. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

3 Figure 2 Baseline values and percent change from baseline in selected nontraditional lipid-related parameters at weeks 4 and week 16. P values for results presented as mean values were obtained from an ANCOVA model with treatment as a fixed effect and baseline as a covariate; P values for results presented as median values were from ANCOVA models on normalized rank transformed data with treatment as a fixed effect and baseline (original scale) as a covariate. *P < .05; ***P < .0001 vs placebo. Error bars represent ± SE for mean values and ±Q1, Q3 for median values. ANCOVA, analysis of covariance; BID, twice daily; CETP, cholesteryl ester transfer protein; HDL-SAA, high-density lipoprotein serum amyloid A; LCAT, lecithin-cholesterol acyltransferase; LDL, low-density lipoprotein; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated phospholipase A2; SE, standard error. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

4 Figure 3 Comparison of cholesterol efflux (FC efflux and CE efflux) from human macrophages in placebo, tofacitinib 5 mg BID, and tofacitinib 10 mg BID patient groups using different PEG HDL volumes. Error bars represent ± SE. BID, twice daily; CE, cholesteryl ester; FC, free cholesterol; PEG HDL, polyethylene glycol high-density lipoprotein; SE, standard error. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

Download ppt "Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis  Robert Wolk, MD, PhD, DSc, Ehrin J."

Similar presentations

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Volume 93, Issue 6, Pages (June 2018)

Volume 93, Issue 6, Pages (June 2018)
Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis  Martin Adiels,

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis  Martin Adiels,
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
Anti-Psoriatic Therapy Recovers High-Density Lipoprotein Composition and Function  Michael Holzer, Peter Wolf, Martin Inzinger, Markus Trieb, Sanja Curcic,

Anti-Psoriatic Therapy Recovers High-Density Lipoprotein Composition and Function  Michael Holzer, Peter Wolf, Martin Inzinger, Markus Trieb, Sanja Curcic,
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.

Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,

Similar presentations

Ads by Google